<DOC>
	<DOCNO>NCT00189293</DOCNO>
	<brief_summary>The purpose study compare recurrence rate follow total clearance external genital wart ( EGWs ) clearance obtain imiquimod ( 3 application per week 4 week ) follow ablative therapy ( laser electrocautery therapy ) ablative therapy treatment alone .</brief_summary>
	<brief_title>Study Imiquimod Cream Prior Ablative Therapy External Ano-Genital Warts</brief_title>
	<detailed_description>To compare recurrence rate 24 week ablative therapy subject external genital wart trated imiquimod , 3 application per week 4 week follow ablative therapy versus vehicle , 3 application per week 4 week follow ablative therapy . A recurrence define investoigator-assessed occurrence lesion ( ) within baseline area clear treatment : imiquimod/vehicle ablative therapy ( either initial ablative ther√°py session ( A0 ) , require complete clearance baseline lesion , second ablative therapy session ( A2 ) .</detailed_description>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Subjects least 1 visible genital perianal wart Total wart area 1 40 square centimeter . Pregnant lactating woman Known sexually transmitted disease Evidence clinically significant immunodeficiency Evidence unstable cardiovascular , pulmonary , hematological , hepatic , renal , endocrine , collagen vascular , neurological gastrointestinal abnormality disease . Treatment within 4 week prior Randomization Visit follow systemic topical treatment : interferon , interferon inducer , immunomodulators , immunosuppressive drug , antiviral drug ( except systemic acyclovir , valacyclovir famciclovir ) , cytotoxic drug , investigational drug , drug know major organ toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>External Ano-Genital Warts</keyword>
	<keyword>Ablative Therapy</keyword>
	<keyword>Aldara</keyword>
</DOC>